26 completed. 26 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 26 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Pasteurellaceae Infections: new trials by email Literature Review of Pasteurellaceae Infections trials Research Report on Pasteurellaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| Exploratory Clinical Study of MT-2301 Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV, Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV, Haemophilus influenza type b conjugate vaccine + DPT-IPV - Haemophilus Influenza Type b | Phase 2 | Completed | Tanabe Pharma Corporation | 154 | 2014-04-01 | 2026-03-17 |
| Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants Pneumococcal conjugate vaccine GSK2830929A, Pneumococcal conjugate vaccine GSK2830930A, Synflorix™ - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 953 | 2012-07-11 | 2019-07-16 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
| Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants Pneumococcal vaccine GSK 2189242A (LD formulation 1), Pneumococcal vaccine GSK 2189242A (HD formulation 2), Synflorix™ - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 1320 | 2011-02-09 | 2019-06-19 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis | Phase 2 | Completed | GlaxoSmithKline | 721 | 2010-12-09 | 2018-08-20 |
| Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants Pneumococcal vaccine GSK 2189242A (LD formulation 1), Pneumococcal vaccine GSK 2189242A (HD formulation 2), Synflorix - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 576 | 2010-09-27 | 2019-05-29 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose GSK2202083A vaccine, Infanrix hexa™, Menjugate™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 391 | 2010-08-18 | 2020-01-21 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™ - Tetanus, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 480 | 2010-05-17 | 2018-08-20 |
| Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers GSK2036874A vaccine, Zilbrix™/Hib vaccine, Poliorix™ - Haemophilus Influenzae Type b, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 312 | 2010-05-13 | 2019-10-01 |
| Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination Pneumococcal vaccine GSK2189242A (formulation 1), Pneumococcal vaccine GSK2189242A (formulation 2), Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3) - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 257 | 2009-11-24 | 2020-11-05 |
| Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age GSK2202083A vaccine, 10-valent pneumococcal vaccine (GSK 1024850A), Infanrix hexa™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 421 | 2009-08-13 | 2020-01-03 |
| Nontypeable H. Influenzae in Healthy Adults NTHi Strain 2019 - Haemophilus Influenzae (NTHI) | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2009-08-01 | 2013-04-11 |
| Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants GSK2197870A, Prevenar™, Menitorix™ - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 2 | Completed | GlaxoSmithKline | 284 | 2009-06-24 | 2018-06-06 |
| Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine Infanrix Hexa - Acellular Pertussis, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 403 | 2008-02-01 | 2018-06-06 |
| Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age Infanrix hexa Vaccine - Acellular Pertussis, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 450 | 2006-10-01 | 2016-11-04 |
| Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC - Diphtheria, Pertussis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 460 | 2006-08-01 | 2014-01-14 |
| Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 Pneumococcal (vaccine) - Acellular Pertussis, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 689 | 2005-11-01 | 2016-09-23 |
| Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines MenHibrix (Hib-MenCY-TT), Infanrix® Penta, Prevenar® - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 2 | Completed | GlaxoSmithKline | 1104 | 2005-04-11 | 2018-07-19 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants DTaP-IPV-HB-PRP~T, DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine - Diphtheria, Tetanus | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 624 | 2004-10-01 | 2013-12-17 |
Showing 20 of 26. Sign in to see all of them.
Haemophilus Infections (26) · Diphtheria (15) · Hepatitis B (15) · Tetanus (15) · Poliomyelitis (12) · Whooping Cough (5) · Streptococcal Infections (4) · Meningococcal Infections (1)
Bacterial Infections (26) · Bacterial Infections and Mycoses (26) · Gram-Negative Bacterial Infections (26) · Infections (26) · Gram-Positive Bacterial Infections (19) · Actinomycetales Infections (15) · Blood-Borne Infections (15) · Clostridium Infections (15) · Communicable Diseases (15) · Corynebacterium Infections (15) · DNA Virus Infections (15) · Digestive System Diseases (15) · Hepadnaviridae Infections (15) · Hepatitis (15)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (11) · 13-valent pneumococcal vaccine (5) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (4) · Heptavalent Pneumococcal Conjugate Vaccine (4) · PHiD-CV vaccine (4) · Hib-MenCY-TT vaccine (3) · DTPa-HBV-IPV combined vaccine (2) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (2) · 10-valent pneumococcal vaccine (1) · Chickenpox Vaccine (1) · DTP-IPV-Hib vaccine (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Hiberix (1) · Meningococcal Vaccines (1) · PEDIARIX (1)
GlaxoSmithKline (21) · Sanofi Pasteur, a Sanofi Company (2) · LG Chem (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Tanabe Pharma Corporation (1)
Germany (5) · Finland (4) · Poland (4) · Czechia (3) · Philippines (3) · Australia (2) · Canada (2) · Dominican Republic (2) · United States (2) · Argentina (1) · Belgium (1) · France (1) · Japan (1) · South Korea (1) · Spain (1)
Edison Alberto, MD (1) · Josefina Carlos, MD (1) · Takashi Nakano, M.D., Ph.D. (1)
PMID 28340322, PMID 20657177, PMID 21372751, PMID 23241989, PMID 24346596
2009 (2), 2016 (1)